Physician profile
Ken Richards
NPI 1477545937
$8,843.43
in general payments reported to CMS, 2019-2025
13 companies · $8,325 in 2025
The $8,325 reported for 2025 was more than what 94% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.60 · 2021: $21.79 · 2022: $154 · 2023: $97.23 · 2024: $187 · 2025: $8,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Travel and Lodging: $1,631 · Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Travel and Lodging | $1,630.58 |
| Food and Beverage | $1,478.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,148.92 | 2025 | |
| Davol INC. | $1,088.31 | 2025 | Phasix Mesh |
| Smith+Nephew, INC. | $277.71 | 2019-2025 | Collagenase Santyl, Regranex |
| Kerecis Limited | $80.08 | 2022-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Organogenesis INC. | $45.59 | 2023-2024 | Puraply |
| Reprise Biomedical, INC. | $36.69 | 2024 | Miro3d |
| Hartmann USA, INC. | $34.73 | 2024-2025 | Zetuvit Plus 10x10 P10 |
| Bioventus LLC | $31.76 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $27.32 | 2024 | Exparel |
| Mayne Pharma Commercial LLC | $23.22 | 2019 | |
| Edwards Lifesciences Corporation | $21.79 | 2021 | |
| Merck Sharp & Dohme LLC | $15.30 | 2023 | Bridion |
| Abbvie INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ken Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.